Evido promotes Lancet Commission on liver health in primary care
The commission emphasizes early detection and management of liver disease, featuring LiverPRO as a screening tool for steatotic liver disease.
See the latest news and media coverage for Evido. We track all announcements, press releases, and industry mentions in real time, all in one place.
AI-driven chronic liver disease detection software
evido.healthLast updated
In short: Evido expanded its liver health impact through a strategic Roche partnership and clinical validation of its LiverPRO screening technology.
The commission emphasizes early detection and management of liver disease, featuring LiverPRO as a screening tool for steatotic liver disease.
It shows 71% fewer unnecessary referrals and 29% lower cost per detected case versus FIB-4 for liver fibrosis detection in SLD patients.
Studies at EASL SLDSummit2026 show LiverPRO improves fibrosis risk stratification, identifying more cases and reducing misses.
LiverPRO is recommended as a scalable first-line non-invasive test for liver fibrosis in steatotic liver disease using routine blood data.
After leaving Coloplast in May, Villumsen has embarked on a career as a board member and investor.
Evido Health gains muscle partnering with Roche to more effectively sell its software solution for early detection of chronic liver disease,...
The company has developed software that uses artificial intelligence (AI) to detect liver diseases based on so-called biomarkers in patient blood samples.
Track Evido and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.